In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.91 below Sera Prognostics Inc average.

Within Medical Laboratories industry 17 other companies have achieved higher Quick Ratio than Sera Prognostics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1424, from total ranking in the first quarter 2026 at 1914.

Explain Quick Ratio?
How much Cash & cash equivalents SERA�s has?
What are SERA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SERA Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	3.19 %	0.08 %	-2.35 %	-2.82 %	-4.67 %
Y / Y Cash & cash equivalent Change	15.65 %	2.61 %	-15.22 %	-12.96 %	-21.16 %
Quick Ratio MRQ	1.91	2.02	1.62	1.84	1.7
SERA's Total Ranking	# 1424	# 1914	# 1642	# 1765	# 1657
Seq. Current Liabilities Change	4 %	-3.18 %	2.93 %	-0.43 %	0.86 %
Seq. Cash & cash equivalent Change	-2.02 %	20.92 %	-9.47 %	7.83 %	-13.07 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 18
Healthcare Sector	# 511
Overall Market	# 1445

Quick Ratio Statistics
High	Average	Low
33.86	7.42	1.56
(Sep 30 2021)		(Dec 31 2020)

Financial Statements
Sera Prognostics Inc 's Current Liabilities	$ 24 Millions	Visit SERA's Balance sheet
Sera Prognostics Inc 's Cash & cash equivalent	$ 46 Millions	Visit SERA's Balance sheet
Source of SERA's Sales		Visit SERA's Sales by Geography

Cumulative Sera Prognostics Inc 's Quick Ratio

SERA's Quick Ratio for the trailling 12 Months

SERA Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-0.51 %	-2.47 %	-3.65 %	-2.73 %	9.9 %
Y / Y Cash & cash equivalent TTM Growth	-3.29 %	-11.94 %	-15.53 %	-13.24 %	-8.42 %
Quick Ratio TTM	1.85	1.8	1.78	1.85	1.9
Total Ranking TTM	# 2922	# 3344	# 2548	# 2658	# 2730
Seq. Current Liabilities TTM Growth	0.8 %	0.02 %	-0.61 %	-0.71 %	-1.19 %
Seq. Cash & cash equivalent TTM Growth	3.7 %	0.71 %	-4 %	-3.54 %	-5.58 %

Quick ratio ranking by company, industry and sector >> Back to SERA Financial Strength Comparisons >> Go to Compare SERA Quick Ratio to its Competitors

On the trailing twelve months basis SERA Cash & cash equivalent increased by 15.65 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Sera Prognostics Inc 's Quick Ratio to 1.85, Quick Ratio remained below SERA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 36 other companies have achieved higher Quick Ratio than Sera Prognostics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3098.

Explain Quick Ratio?
How much Cash & cash equivalents SERA�s has?
What are SERA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 37
Healthcare Sector	# 909
Within the Market	# 1424

trailing twelve months Quick Ratio Statistics
High	Average	Low
13.39	3.11	0.16
(Mar 31 2022)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Castle Biosciences Inc	4.72	$ 266.805 Millions	$ 56.509 Millions
Bionexus Gene Lab Corp	4.33	$ 3.522 Millions	$ 0.813 Millions
Caredx Inc	3.99	$ 373.636 Millions	$ 93.698 Millions
Omniab Inc	3.78	$ 51.995 Millions	$ 13.758 Millions
Fulgent Genetics Inc	3.58	$ 257.032 Millions	$ 71.756 Millions
Guardant Health Inc	3.11	$ 1,053.469 Millions	$ 338.962 Millions
Butterfly Network Inc	2.13	$ 124.659 Millions	$ 58.603 Millions
Natera Inc	1.97	$ 1,091.502 Millions	$ 553.200 Millions
Biodesix Inc	1.96	$ 29.996 Millions	$ 15.291 Millions
Sera Prognostics Inc	1.91	$ 46.445 Millions	$ 24.356 Millions
Exagen Inc	1.83	$ 24.588 Millions	$ 13.457 Millions
Radnet Inc	1.11	$ 773.510 Millions	$ 697.822 Millions
Bioaffinity Technologies Inc	0.91	$ 2.430 Millions	$ 2.681 Millions
Ispecimen inc	0.43	$ 4.426 Millions	$ 10.196 Millions
Quest Diagnostics Inc	0.40	$ 720.000 Millions	$ 1,788.000 Millions
Lumexa Imaging Holdings Inc	0.39	$ 69.705 Millions	$ 178.355 Millions

Date modified: 2026-09-12T06:25:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.